We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Axsome Therapeutics
AXSM
$12B
| $527K | ﹤0.01% |
5,106
-899
| -15% | -$36.3K |
|
777
Bruker
BRKR
$9.48B
| $527K | ﹤0.01% |
10,340
| – | – |
|
778
Essex Property Trust
ESS
$19B
| $523K | ﹤0.01% |
1,739
+1,615
| +1,302% | +$510K |
|
779
AerCap
AER
$24.1B
| $518K | ﹤0.01% |
8,429
-219
| -3% | -$12.9K |
|
|
CVGW
780
DELISTED
Calavo Growers
CVGW
| $518K | ﹤0.01% |
5,728
+303
| +6% | +$27.1K |
|
781
State Street Materials Select Sector SPDR ETF
XLB
$8.82B
| $518K | ﹤0.01% |
16,920
| – | – |
|
782
ICF International
ICFI
$1.5B
| $516K | ﹤0.01% |
5,640
+5,590
| +11,180% | +$481K |
|
783
ResMed
RMD
$30.3B
| $516K | ﹤0.01% |
3,334
+421
| +14% | +$60.7K |
|
784
Vanguard Extended Market ETF
VXF
$30.4B
| $513K | ﹤0.01% |
4,075
-476
| -10% | -$57.5K |
|
785
Boston Properties
BXP
$11.2B
| $512K | ﹤0.01% |
3,722
-484
| -12% | -$65.2K |
|
786
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
$2.77B
| $511K | ﹤0.01% |
18,715
+330
| +2% | +$8.69K |
|
787
Princeton Bancorp
BPRN
$289M
| $510K | ﹤0.01% |
16,200
| – | – |
|
788
Silicon Laboratories
SLAB
$7.18B
| $510K | ﹤0.01% |
4,403
+860
| +24% | +$94.3K |
|
789
Agnico Eagle Mines
AEM
$71.6B
| $509K | ﹤0.01% |
8,274
-10
| -0.1% | -$581 |
|
790
American Financial Group
AFG
$12.1B
| $507K | ﹤0.01% |
4,638
+4,458
| +2,477% | +$477K |
|
|
CHX
791
DELISTED
ChampionX
CHX
| $507K | ﹤0.01% |
15,078
+11,345
| +304% | +$309K |
|
|
BRKL
792
DELISTED
Brookline Bancorp
BRKL
| $506K | ﹤0.01% |
30,791
+1,650
| +6% | +$26K |
|
793
EPAM Systems
EPAM
$5.2B
| $501K | ﹤0.01% |
2,369
-515
| -18% | -$101K |
|
794
Fox Factory Holding Corp
FOXF
$808M
| $498K | ﹤0.01% |
7,172
+5,600
| +356% | +$361K |
|
795
Hilton Grand Vacations
HGV
$4.1B
| $498K | ﹤0.01% |
14,489
+664
| +5% | +$22.8K |
|
|
AMJ
796
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
| $492K | ﹤0.01% |
22,580
+20,708
| +1,106% | +$446K |
|
797
Palo Alto Networks
PANW
$263B
| $487K | ﹤0.01% |
12,648
+498
| +4% | +$18.8K |
|
|
LPT
798
DELISTED
Liberty Property Trust
LPT
| $487K | ﹤0.01% |
8,120
+5,983
| +280% | +$343K |
|
799
Martin Marietta Materials
MLM
$34.9B
| $486K | ﹤0.01% |
1,739
-149
| -8% | -$39.7K |
|
800
Westamerica Bancorp
WABC
$1.4B
| $483K | ﹤0.01% |
7,143
+2,000
| +39% | +$131K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.